Search - tctmd.com

Displaying 141 - 160 of 197

Sort: Relevancy | Date

News Daily News

Biomarker Levels ID Patients With Most to Gain From Intensive BP Lowering

Todd Neale

September 08, 2021

News Opinion CV Team Dispatch

September 2021 News Roundup

L.A. McKeown

September 01, 2021

News Opinion CV Team Dispatch

July/August 2021 News Roundup

L.A. McKeown

August 01, 2021

News Daily News

ARBs Preferable to ACE Inhibitors in Large Observational Hypertension Study

Michael O'Riordan

July 27, 2021

News Daily News

Making the Case for Sex-Specific CVD Guidelines

L.A. McKeown

July 08, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Opinion CV Team Dispatch

April 2021 News Roundup

L.A. McKeown

April 10, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

Caitlin E. Cox

March 24, 2021

News Opinion CV Team Dispatch

March 2021 News Roundup

L.A. McKeown

March 01, 2021

News Opinion CV Team Dispatch

February 2021 News Roundup

L.A. McKeown

February 01, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Daily News

More Than Half of All HF Patients Take 10 or More Meds

L.A. McKeown

October 20, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

Advertisement

Biomarker Levels ID Patients With Most to Gain From Intensive BP Lowering

September 2021 News Roundup

July/August 2021 News Roundup

ARBs Preferable to ACE Inhibitors in Large Observational Hypertension Study

Making the Case for Sex-Specific CVD Guidelines

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Less Cancer Among HF Patients Taking Statins, Registry Shows

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

FDA Approves Dapagliflozin for CKD Patients

April 2021 News Roundup

Roughly 80% of ESC Guideline Writers Have Financial COIs

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

March 2021 News Roundup

February 2021 News Roundup

FDA Approves Vericiguat for High-risk Patients With HF

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

More Than Half of All HF Patients Take 10 or More Meds

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content